Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 | 7.54 | 5.63 | 13.19 | 0.30 |
Net Debt/EBITDA |
1.60 | 1.99 | 1.20 | 1.43 | 2.31 | 6.25 | 0.63 | 0.92 | 1.32 | (0.46) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 288.21% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.28) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.37 | 1.31 | 0.34 | 0.32 | 0.84 | 0.67 | 0.87 | 0.85 | 1.14 | 0.87 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.03 |
| (63.56%) | (518.40%) | (652.92%) | (70.89%) | (19.46%) | (22.80%) | (133.66%) | (82.87%) | (156.79%) | (19.17%) | |
| (26.34%) | (27.16%) | (128.16%) | (66.81%) | (18.77%) | (21.92%) | (114.54%) | (74.19%) | (118.76%) | (16.35%) | |
ROIC |
(1,511.24%) | 0.00% | 0.00% | (198.99%) | (29.11%) | (15.11%) | (1,488.41%) | (578.13%) | (381.60%) | 0.00% |
Return on Tangible Assets |
(38.87%) | (27.38%) | (223.11%) | (165.84%) | (41.11%) | (20.16%) | (185.01%) | (119.64%) | (74.59%) | 208.13% |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.25 | 0.00 | 0.11 | 0.09 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.76) | (0.97) | (1.61) | (1.99) | (1.95) | (10.48) | (21.12) | (23.75) | (57.41) | (231.08) |
Cash per Share |
1.63 | 2.89 | 2.08 | 3.95 | 5.72 | 78.70 | 13.40 | 25.91 | 66.52 | 52.44 |
Shareholders Equity per Share |
1.67 | 2.43 | 0.29 | 5.89 | 11.07 | 131.35 | 14.43 | 28.94 | 74.79 | (126.85) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.67 | 2.43 | 0.29 | 5.89 | 11.07 | 131.35 | 14.43 | 28.94 | 74.79 | (126.85) |
Free Cash Flow |
(62.34) | (47.27) | (39.53) | (28.42) | (28.91) | (15.21) | (13.86) | (11.89) | (14.93) | (4.92) |
Working Capital |
117.34 | 132.15 | 52.23 | 53.04 | 83.95 | 113.15 | 8.65 | 11.74 | 17.56 | (2.75) |
Capital Expenditures |
— | — | — | — | — | — | — | — | 0.01 | 0.00 |
Net Current Asset Value |
103.46 | 84.47 | (25.73) | 50.91 | 81.79 | 109.04 | 8.51 | 11.74 | 17.56 | (2.75) |
| Other line items | ||||||||||
Quick Ratio |
7.27 | 12.11 | 13.12 | 8.71 | 19.28 | 45.99 | 6.65 | 5.12 | 12.02 | 0.29 |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 409.80 | 0.79 | 0.88 | 1.13 |
Cash ROIC |
(23.08%) | (18.30%) | (67.79%) | (20.22%) | (11.62%) | (4.99%) | (75.90%) | (43.30%) | (40.63%) | (264.34%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.76) | (0.97) | (1.61) | (1.99) | (1.95) | (10.48) | (21.12) | (23.75) | (57.44) | (231.13) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 |
Average Receivables |
— | — | — | — | — | 0.18 | 0.18 | — | — | — |
Average Payables |
4.73 | 3.40 | 1.58 | 2.01 | 1.59 | 0.85 | 0.51 | 0.55 | 0.38 | 0.77 |
Average Assets |
173.21 | 133.24 | 90.93 | 131.67 | 183.87 | 104.06 | 13.98 | 18.96 | 11.04 | 34.59 |
Average Common Equity |
71.77 | 6.98 | 17.85 | 124.09 | 177.30 | 100.03 | 11.98 | 16.97 | 8.37 | 29.50 |
Capex to Sales |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Columns are period end dates